{"_buckets": {"deposit": "6ce664ab-98b9-47bf-a3c9-b21bf043e5b7"}, "_deposit": {"id": "6497", "owners": [], "pid": {"revision_id": 0, "type": "depid", "value": "6497"}, "status": "published"}, "_oai": {"id": "oai:niigata-u.repo.nii.ac.jp:00006497"}, "item_7_biblio_info_6": {"attribute_name": "\u66f8\u8a8c\u60c5\u5831", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "1994-09", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "3", "bibliographicPageEnd": "128", "bibliographicPageStart": "123", "bibliographicVolumeNumber": "42", "bibliographic_titles": [{"bibliographic_title": "Acta medica et biologica"}, {"bibliographic_title": "Acta medica et biologica", "bibliographic_titleLang": "en"}]}]}, "item_7_description_4": {"attribute_name": "\u6284\u9332", "attribute_value_mlt": [{"subitem_description": "In order to assess its effects on blood pressure and serum lipids, doxazosin was administered to patients with essential hypertension and a serum total cholesterol level above 220 mg/dl as part of a multicenter trial in which 7 institutions in Niigata Prefecture participated. Doxazosin was given either as monotherapy or in combination with some other antihypertensive agent. The systolic, diastolic, and mean blood pressures were all decreased significantly at weeks 4, 8 and 12 of treatment, while there was no change in the heart rate throughout the study. The antihypertensive effects in individual patients were rated according to the \"Guideline for Clinical Evaluation of Antihypertensive Drugs.\" Moderate or improved reduction of blood pressure was attained in 29/39 patients (74%) after 12 weeks of treatment. Total cholesterol and low density lipoprotein (LDL) cholesterol levels decreased significantly after doxazosin treatment, while the cholesterol ratio (high density lipoprotein (HDL) cholesterol/total cholesterol) increased significantly. Although the apoprotein A_1 level remained unchanged, the apoprotein B level decreased significantly, and the apoprotein A_1/apoprotein B ratio increased significantly as a consequence. These results suggest that doxazosin is a useful antihypertensive drug which may be used as a first choice therapy in patients with essential hypertension and high serum cholesterol level.", "subitem_description_type": "Abstract"}]}, "item_7_publisher_7": {"attribute_name": "\u51fa\u7248\u8005", "attribute_value_mlt": [{"subitem_publisher": "Niigata University School of Medicine"}]}, "item_7_select_19": {"attribute_name": "\u8457\u8005\u7248\u30d5\u30e9\u30b0", "attribute_value_mlt": [{"subitem_select_item": "publisher"}]}, "item_7_source_id_11": {"attribute_name": "\u66f8\u8a8c\u30ec\u30b3\u30fc\u30c9ID", "attribute_value_mlt": [{"subitem_source_identifier": "AA00508361", "subitem_source_identifier_type": "NCID"}]}, "item_7_source_id_9": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "05677734", "subitem_source_identifier_type": "ISSN"}]}, "item_creator": {"attribute_name": "\u8457\u8005", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Watanabe, Kenichi"}], "nameIdentifiers": [{"nameIdentifier": "53212", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Hirokawa, Yoichi"}], "nameIdentifiers": [{"nameIdentifier": "53213", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Hirosawa, Hideo"}], "nameIdentifiers": [{"nameIdentifier": "53214", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ohara, Kazuhiko"}], "nameIdentifiers": [{"nameIdentifier": "53215", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kamimura, Akira"}], "nameIdentifiers": [{"nameIdentifier": "53216", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yoshida, Hideharu"}], "nameIdentifiers": [{"nameIdentifier": "53217", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Furukawa, Nobuo"}], "nameIdentifiers": [{"nameIdentifier": "53218", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Shibata, Akira"}], "nameIdentifiers": [{"nameIdentifier": "53219", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "\u30d5\u30a1\u30a4\u30eb\u60c5\u5831", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2019-08-06"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "42(3)_123-128.pdf", "filesize": [{"value": "598.1 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 598100.0, "url": {"label": "42(3)_123-128.pdf", "url": "https://niigata-u.repo.nii.ac.jp/record/6497/files/42(3)_123-128.pdf"}, "version_id": "778013c8-92dd-4ee8-86cf-8362586b7ae8"}]}, "item_language": {"attribute_name": "\u8a00\u8a9e", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "\u8cc7\u6e90\u30bf\u30a4\u30d7", "attribute_value_mlt": [{"resourcetype": "departmental bulletin paper", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Effects of Doxazosin Mesilate on Blood Pressure and Serum Lipids in Hypertensive Patients", "item_titles": {"attribute_name": "\u30bf\u30a4\u30c8\u30eb", "attribute_value_mlt": [{"subitem_title": "Effects of Doxazosin Mesilate on Blood Pressure and Serum Lipids in Hypertensive Patients"}, {"subitem_title": "Effects of Doxazosin Mesilate on Blood Pressure and Serum Lipids in Hypertensive Patients", "subitem_title_language": "en"}]}, "item_type_id": "7", "owner": "1", "path": ["453/456", "471/537/568/626"], "permalink_uri": "http://hdl.handle.net/10191/33249", "pubdate": {"attribute_name": "\u516c\u958b\u65e5", "attribute_value": "2015-09-04"}, "publish_date": "2015-09-04", "publish_status": "0", "recid": "6497", "relation": {}, "relation_version_is_last": true, "title": ["Effects of Doxazosin Mesilate on Blood Pressure and Serum Lipids in Hypertensive Patients"], "weko_shared_id": null}